Therefore, in recent years, many studies have focused on the PI3K/AKT/mTOR/SREBP‐1 signaling pathway and attempted to identify inhibitors of the PI3K/AKT/mTOR/SREBP‐1 signaling pathway to control the occurrence and development of hyperlipidemia [21, 22, 23, 24]. The gene discussed is MTOR; the disease is hyperlipidemia.